Objectives: This paper aims to identify relevant potential predictors of medical genetic counseling for breast cancer (MGC-BC) in primary care and to develop a comprehensive questionnaire to study MGC-BC. Methods: A scoping review was conducted to identify the predictors of MGC-BC among primary care physicians. Relevant articles were identified in selected databases (PubMed, Embase, CINAHL, ISI Web of Science, PsycINFO, and Cochrane CENTRAL) and 4 selected relevant electronic journals. Results: An inductive analysis of the 193 quantitatively tested variables, conducted by 3 researchers, showed that 6 conceptual categories of determinants, namely (1) demographic, (2) organizational, (3) experiential, (4) professional, (5) psychological, and (6) cognitive, influence MGC-BC practices. Conclusion: There is a scarcity of literature addressing the medical behavior determinants of MGC-BC. Future research is needed to identify effective strategies put into action to support the integration of MGC-BC in primary care medical practices and routines. However, our results shed light on 2 levels of actions that could improve genetic counseling services in primary care: (1) medical training and educational efforts emphasizing family history collection (individual level), and (2) clarification of roles and responsibilities in ordering and referral practices in genetic counseling and genetic testing for better healthcare management (organizational level).

Keywords:
Breast cancer, Genetic risk communication, Genetic risk prediction, Medical behavior, Medical genetic counseling, Primary care, Scoping review
1.
Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2.
Murray AJ, Davies DM: The genetics of breast cancer. Surg Annu 2013;31:1-3.
3.
Beaulieu N, Bloom D, Bloom R, Stein R: Breakaway: the global burden of cancer - challenges and opportunities. A report from the economist intelligence unit, 2009. The Economist 2009. http://www.livestrong.org/pdfs/GlobalEconomicImpact.
4.
Apostolou P, Fostira F: Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int 2013;2013:747318.
5.
Khoury MJ, Clauser SB, Freedman AN, Gillanders EM, Glasgow RE, Klein WM, Schully SD: Population sciences, translational research, and the opportunities and challenges for genomics to reduce the burden of cancer in the 21st century. Cancer Epidemiol Biomarkers Prev 2011;20:2105-2114.
6.
Lynch HT, Snyder C, Lynch J: Hereditary breast cancer: practical pursuit for clinical translation. Ann Surg Oncol 2012;19:1723-1731.
7.
Singh K, Lester J, Karlan B, Bresee C, Geva T, Gordon O: Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers. Am J Obstet Gynecol 2013;208:329.e1-e6.
8.
Erblich J, Brown K, Kim Y, Valdimarsdottir HB, Livingston BE, Bovbjerg DH: Development and validation of a breast cancer genetic counseling knowledge questionnaire. Patient Educ Couns 2005;56:182-191.
9.
Burton H, Chowdhury S, Dent T, Hall A, Pashayan N, Pharoah P: Public health implications from cogs and potential for risk stratification and screening. Nat Genet 2013;45:349-351.
10.
Pashayan N, Hall A, Chowdhury S, Dent T, Pharoah P, Burton H: Public health genomics and personalized prevention: lessons from the cogs project. J Intern Med 2013;274:451-456.
11.
Sivell S, Elwyn G, Gaff CL, Clarke AJ, Iredale R, Shaw C, Dundon J, Thornton H, Edwards A: How risk is perceived, constructed and interpreted by clients in clinical genetics, and the effects on decision making: systematic review. J Genet Couns 2008;17:30-63.
12.
Battista R, Blancquaert I, Laberge AM, van Schendel N, Leduc N: Genetics in health care: an overview of current and emerging models. Public Health Genomics 2012;15:34-45.
13.
Berliner JL, Fay AM: Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the national society of genetic counselors. J Genet Couns 2007;16:241-260.
14.
Smerecnik CMR, Mesters I, Verweij E, de Vries NK, de Vries H: A systematic review of the impact of genetic counseling on risk perception accuracy. J Genet Couns 2009;18:217-228.
15.
Vos J, Oosterwijk JC, Gomez-Garcia E, Menko FH, Collee MJ, van Asperen CJ, Jansen AM, Stiggelbout AM, Tibben A: Exploring the short-term impact of DNA-testing in breast cancer patients: the counselees' perception matters, but the actual BRCA1/2 result does not. Patient Educ Couns 2012;86:239-251.
16.
Meiser B, Tucker K, Friedlander M, Barlow-Stewart K, Lobb E, Saunders C, Mitchell G: Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda. Breast Cancer Res 2008;10:216.
17.
O'Daniel JM: The prospect of genome-guided preventive medicine: a need and opportunity for genetic counselors. J Genet Couns 2010;19:315-327.
18.
Aalfs CM, Smets EMA, De Haes HM, Leschot NJ: Referral for genetic counselling during pregnancy: limited alertness and awareness about genetic risk factors among GPs. Fam Pract 2003;20:135-141.
19.
Shields AE, Burke W, Levy DE: Differential use of available genetic tests among primary care physicians in the United States: results of a national survey. Genet Med 2008;10:404-414.
20.
Guerra CE, Jacobs SE, Holmes JH, Shea JA: Are physicians discussing prostate cancer screening with their patients and why or why not? A pilot study. J Gen Intern Med 2007;22:901-907.
21.
Qureshi N, Armstrong S, Modell B: GPs' opinions of their role in prenatal genetic services: a cross-sectional survey. Fam Pract 2006;23:106-110.
22.
Wideroff L, Freedman AN, Olson L, Klabunde CN, Davis W, Srinath KP, Croyle RT, Ballard-Barbash R: Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev 2003;12:295-303.
23.
Graves KD, Christopher J, Harrison TM, Peshkin BN, Isaacs C, Sheppard VB: Providers' perceptions and practices regarding BRCA1/2 genetic counseling and testing in African American women. J Genet Couns 2011;20:674-689.
24.
Pieterse AH, Ausems MG, Spreeuwenberg P, van Dulmen S: Longer-term influence of breast cancer genetic counseling on cognitions and distress: smaller benefits for affected versus unaffected women. Patient Educ Couns 2011;85:425-431.
25.
Chivers SK, Addington-Hall J, Lucassen AM, Foster CL: What facilitates or impedes family communication following genetic testing for cancer risk? A systematic review and meta-synthesis of primary qualitative research. J Genet Couns 2010;19:330-342.
26.
Edwards A, Gray J, Clarke A, Dundon J, Elwyn G, Gaff C, Hood K, Iredale R, Sivell S, Shaw C: Interventions to improve risk communication in clinical genetics: systematic review. Patient Educ Couns 2008;71:4-25.
27.
Howard AF, Balneaves LG, Bottorff JL: Women's decision making about risk-reducing strategies in the context of hereditary breast and ovarian cancer: a systematic review. J Genet Couns 2009;18:578-597.
28.
Arksey H, O'Malley L: Scoping studies: towards a methodological framework. Int J Soc Res Methodol 2005;8:19-32.
29.
Tinsley HEA, Weiss DJ: Interrater reliability and agreement of subjective judgements. J Couns Psychol 1975;22:358-376.
30.
Dewey ME: Coefficients of agreement. Br J Psychiatry 1983;143:487-489.
31.
Kottner J: Interrater reliability and the kappa statistic: a comment on Morris et al. (2008). Int J Nurs Stud 2009;46:140-141.
32.
Sim J, Wright CC: The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther 2005;85:257-325.
33.
Brennan PF, Hays BJ: The kappa statistic for establishing interrater reliability in the secondary analysis of qualitative clinical data. Res Nurs Health 1992;15:153-161.
34.
Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174.
35.
Tinsley HEA, Weiss DJ: Interrater reliability and agreement; in Tinsley HEA, Brown SD (eds): Handbook of Applied Multivariate Statistics and Mathematical Modeling. San Diego, Academic Press, 2000, pp 95-124.
36.
Godin G, Bélanger-Gravel A, Eccles M, Grimshaw J: Healthcare professionals' intentions and behaviours: a systematic review of studies based on social cognitive theories. Implement Sci 2008;3:1-12.
37.
Landry R: Knowledge transfer as a value creation process: Proceedings from the 17th International Conference on Management of Technology, IAMOT on Creating and Managing a Knowledge Economy. Dubai, UAE, 2008. http://www.buid.ac.ae/iamot2008/.
38.
Faden RR, Tambor ES, Chase GA, Geller G, Hofman KJ, Holtzman NA: Attitudes of physicians and genetics professionals toward cystic fibrosis carrier screening. Am J Med Genet 1994;50:1-11.
39.
Littell JH, Corcoran J, Pillai V: Systematic reviews and meta-analysis. Oxford, Oxford University Press, 2008.
40.
Légaré F, Ratté S, Gravel K, Graham ID: Barriers and facilitators to implementing shared decision-making in clinical practice: update of a systematic review of health professionals' perceptions. Patient Educ Couns 2008;73:526-535.
41.
Ryhanen AM, Siekkinen M, Rankinen S, Korvenranta H, Leino-Kilpi H: The effects of internet or interactive computer-based patient education in the field of breast cancer: a systematic literature review. Patient Educ Couns 2010;79:5-13.
42.
St-Jacques S, Grenier S, Charland M, Forest JC, Rousseau F, Legare F: Decisional needs assessment regarding Down syndrome prenatal testing: a systematic review of the perceptions of women, their partners and health professionals. Prenat Diagn 2008;28:1183-1203.
43.
Kaplan CP, Haas JS, Perez-Stable EJ, Des Jarlais G, Gregorich SE: Factors affecting breast cancer risk reduction practices among California physicians. Prev Med 2005;41:7-15.
44.
Poppelaars FAM, Adèr HJ, Cornel MC, Henneman L, Hermens RPMG, van der Wal G, ten Kate LP: Attitudes of potential providers towards preconceptional cystic fibrosis carrier screening. J Genet Couns 2004;13:31-44.
45.
Thomassen R, Tibben A, Niermeijer MF, Van Der Does E, Van De Kamp JJ, Verhage F: Attitudes of Dutch general practitioners towards presymptomatic DNA-testing for Huntington disease. Clin Genet 1993;43:63-68.
46.
McCahon D, Holder R, Metcalfe A, Clifford S, Gill P, Cole T, Sleightholme HV, Wilson S: General practitioners' attitudes to assessment of genetic risk of common disorders in routine primary care. Clin Genet 2009;76:544-551.
47.
Hindorff LA, Burke W, Laberge AM, Rice KM, Lumley T, Leppig K, Rosendaal FR, Larson EB, Psaty BM: Motivating factors for physician ordering of Factor V Leiden genetic tests. Arch Intern Med 2009;169:68-74.
48.
Kyne G, Maxwell S, Brameld K, Harrison K, Goldblatt J, O'Leary P: Compliance with professional guidelines with reference to familial cancer services. Aust NZJ Public Health 2011;35:226-230.
49.
Clasen CM, Vernon SW, Mullen PD, Jackson GL: A survey of physician beliefs and self-reported practices concerning screening for early detection of cancer. Soc Sci Med 1994;39:841-849.
50.
Verger P, Aulagnier M, Souville M, Ravaud JF, Lussault PY, Garnier JP, Paraponaris A: Women with disabilities: general practitioners and breast cancer screening. Am J Prevent Med 2005;28:215-220.
51.
Keller B, Zemp Stutz E, Tibblin M, Ackermann-Liebrich U, Faisst K, Probst-Hensch N: Screening mammographies in Switzerland: what makes female and male physicians prescribe them? Swiss Med Wkly 2001;131:311-319.
52.
Carroll JC, Cappelli M, Miller F, Wilson BJ, Grunfeld E, Peeters C, Hunter AG, Gilpin C, Prakash P: Genetic services for hereditary breast/ovarian and colorectal cancers - physicians' awareness, use and satisfaction. Community Genet 2008;11:43-51.
53.
Dulai GS, Farmer MM, Ganz PA, Bernaards CA, Qi K, Dietrich AJ, Bastani R, Belman MJ, Kahn KL: Primary care provider perceptions of barriers to and facilitators of colorectal cancer screening in a managed care setting. Cancer 2004;100:1843-1852.
54.
Foo W, Young JM, Solomon MJ, Wright CM: Family history? The forgotten question in high-risk colorectal cancer patients. Colorectal Dis 2009;11:450-455.
55.
Acheson LS, Wiesner GL, Zyzanski SJ, Goodwin MA, Stange KC: Family history-taking in community family practice: implications for genetic screening. Genet Med 2000;2:180-185.
56.
Lazcano-Ponce E, Angeles-Llerenas A, Alvarez-Del Rio A, Salazar-Martinez E, Allen B, Hernandez-Avila M, Kraus A: Ethics and communication between physicians and their patients with cancer, HIV/AIDS, and rheumatoid arthritis in Mexico. Arch Med Res 2004;35:66-75.
57.
McCann S, MacAuley D, Barnett Y: Genetic consultations in primary care: GPs' responses to three scenarios. Scand J Prim Health Care 2005;23:109-114.
58.
Wolf MS, Baker DW, Makoul G: Physician-patient communication about colorectal cancer screening. J Gen Intern Med 2007;22:1493-1499.
59.
Geller G, Tambor ES, Chase GA, Hofman KJ, Faden RR, Holtzman NA: Incorporation of genetics in primary care practice: will physicians do the counseling and will they be directive? Arch Fam Med 1993;2:1119-1125.
60.
Escher M, Sapino A-P: Primary care physicians' knowledge and attitudes towards genetic testing for breast-ovarian cancer predisposition. Ann Oncol 2000;11:1131-1135.
61.
Freedman AN, Wideroff L, Olson L, Davis W, Klabunde C, Srinath KP, Reeve BB, Croyle RT, Ballard-Barbash R: US physicians' attitudes toward genetic testing for cancer susceptibility. Am J Med Genet A 2003;120A:63-71.
62.
Keating NL, Stoeckert KA, Regan MM, DiGianni L, Garber JE: Physicians' experiences with BRCA1/2 testing in community settings. J Clin Oncol 2008;26:5789-5796.
63.
Acton RT, Burst NM, Casebeer L, Ferguson SM, Greene P, Laird BL, Leviton L: Knowledge, attitudes, and behaviors of Alabama's primary care physicians regarding cancer genetics. Acad Med 2000;75:850-852.
64.
Haas JS, Kaplan CP, Gregorich SE, Perez-Stable EJ, Des Jarlais G: Do physicians tailor their recommendations for breast cancer risk reduction based on patient's risk? J Gen Intern Med 2004;19:302-309.
65.
Tyler CV Jr, Snyder CW: Cancer risk assessment: examining the family physician's role. J Am Board Fam Med 2006;19:468-477.
66.
Sifri R, Myers R, Hyslop T, Turner B, Cocroft J, Rothermel T, Grana J, Schlackman N: Use of cancer susceptibility testing among primary care physicians. Clin Genet 2003;64:355-360.
67.
Borry P, Goffin T, Nys H, Dierickx K: Attitudes regarding predictive genetic testing in minors: a survey of European clinical geneticists. Am J Med Genet C Semin Med Genet 2008;148C:78-83.
68.
Guerra CE, Sherman M, Armstrong K: Diffusion of breast cancer risk assessment in primary care. J Am Board Fam Med 2009;22:272-279.
69.
Geller G, Tambor ES, Chase GA, Holtzman NA: Measuring physicians' tolerance for ambiguity and its relationship to their reported practices regarding genetic testing. Med Care 1993;31:989-1001.
70.
Vig HS, Armstrong J, Egleston BL, Mazar C, Toscano M, Bradbury AR, Daly MB, Meropol NJ: Cancer genetic risk assessment and referral patterns in primary care. Genet Test Mol Biomarkers 2009;13:735-741.
71.
Costanza ME, Stoddard AM, Zapka JG, Gaw VP, Barth R: Physician compliance with mammography guidelines: barriers and enhancers. J Am Board Fam Pract 1992;5:143-152.
72.
National Comprehensive Cancer Network: NCCN guidelines for detection, prevention, & risk reduction, genetic/familial high-risk assessment: Breast and ovarian, 2011. www.nccn.org/index.asp.
73.
National Comprehensive Cancer Network: Criteria for consideration of BRCA1/2 genetic testing, 2013. www.nccn.org.
74.
Najafzadeh M, Lynd LD, Davis JC, Bryan S, Anis A, Marra M, Marra CA: Barriers to integrating personalized medicine into clinical practice: a best-worst scaling choice experiment. Genet Med 2012;14:520-526.
75.
Haga SB, Burke W, Agans R: Primary-care physicians' access to genetic specialists: an impediment to the routine use of genomic medicine? Genet Med 2013;15:513-514.
76.
Wood M, Flynn B, Stockdale A: Primary care physician management, referral, and relations with specialists concerning patients at risk for cancer due to family history. Public Health Genomics 2013;16:75-82.
77.
Gorin SS, Ashford AR, Lantigua R, Hajiani F, Franco R, Heck JE, Gemson D: Intraurban influences on physician colorectal cancer screening practices. J Natl Med Assoc 2007;99:1371-1380.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.